SPECIAL REPORT
Real-world efficacy and safety
Switching anti-CD20 therapies
Patient-reported outcomes (PROs)
Effect on cortical lesions Read More
Neurology
ACTRIMS Forum 2025 Highlights – Saturday, March 1, 2025
March 1, 2025The following summarizes some of the highlights from Day 2 if the Americas Committee for Treatment and Research in MS (ACTRIMS) Forum 2025.
ACTRIMS Forum 2025 Highlights – Friday, February 28, 2025
February 28, 2025The following summarizes some of the highlights from Day 1 of the Americas Committee for Treatment and Research in MS (ACTRIMS) Forum 2025.
sNfL useful in prognosis for first demyelinating event
February 20, 2025A new study reports that obtaining neurofilament-light chain levels in patients with a first demyelinating event is useful to identify those at risk of developing multiple sclerosis (Cornabella et al. Neurol Neuroimmunol Neuroinflamm 2025;12:e200370). Read More
Adjunctive cenobamate for focal epilepsy – data review and use in clinical practice
February 11, 2025Summarizes phase II and III data on cenobamate as adjunctive therapy for partial-onset seizures. Includes expert recommendations on adjusting dosing of other antiseizure medications when initiating cenobamate.
13 slides